Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06864169 | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | PHASE2 | ACTIVE NOT_RECRUITING | 160 | — | — | Apr 1, 2025 | Jan 4, 2029 | Apr 23, 2026 | 41 | United States, Argentina +8 |
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.
| Arm | Type | Description |
|---|---|---|
| Raludotatug Deruxtecan (R-DXd) | EXPERIMENTAL | R-DXd will be administered via IV infusion. |
| Name | Type | Description |
|---|---|---|
| Raludotatug Deruxtecan (R-DXd) | BIOLOGICAL | Administered via intravenous (IV) infusion. |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has one of the following cancers: * Unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) * Unresectable or metastatic adenocarcinoma of the biliary tract \[intra- or extrahepatic hola...